>
Nancy Pelosi's Corpse Rolled Out at Oxford Union to Denounce Populism
The Financial Incentive to Murder and Poison American Children
Walmart Soars To Record High After Beating Estimates, Guiding Higher As Consumers...
Brighteon Broadcast News, May 16, 2024 – MASS MENTAL ILLNESS exploding across Western...
A Staggering 19x Energy Jump in Capacitors May Be the Beginning of the End for Batteries
Telegram Disabled My Account. Good Riddance
China's floating nuke plants up South China Sea ante
'Tungsten wall' leads to nuclear fusion breakthrough
Matt Taibbi Uncensored: Finance A 'Street Scam'
This Bonkers 656-Foot 'AirYacht' Concept Can Transport 40 Guests Around the World
DR. BRYAN ARDIS | How Much Nicotine Should You Use? How It Can Heal Parkinson's and More...
Elon Musk's Neuralink begins clinical trials in Phoenix
Scientists Are Making Jet Fuel from Landfill Gas Aiming to Launch Circular Economy
It's opened the door to developing a drug to treat the condition for which existing painkillers do little.
Diabetes, chemotherapy drugs, multiple sclerosis, injuries and amputations have all been associated with neuropathic pain, usually caused by damage to nerves in various body tissues, including the skin, muscles and joints. Mechanical hypersensitivity – or mechanical allodynia – is a major symptom of neuropathic pain, where innocuous stimuli like light touch cause severe pain.
Many available pain medications aren't effective in reducing this often-debilitating type of chronic pain. However, researchers at the University of Texas at Austin (UT Austin), in collaboration with UT Dallas and the University of Miami, may have advanced the treatment of neuropathic pain by discovering a molecule that reduces mechanical hypersensitivity in mice.
"We found it to be an effective painkiller, and the effects were rather long-lived," said Stephen Martin, a co-corresponding author of the study. "When we tested it on different models, diabetic neuropathy and chemotherapy-induced neuropathy, for example, we found this compound has an incredible beneficial effect."
The compound is FEM-1689, which binds to the sigma 2 receptor (σ2R), which was identified in 2017 as transmembrane protein 97 (TMEM97). The researchers had previously found that several small molecules that bind selectively to σ2R/TMEM97 produce strong and long-lasting anti-neuropathic pain effects in mice. FEM-1689, one such small molecule, was found to have improved selectivity for σ2R/TMEM97.